ACETYLLEUCINE, L-

Possibly Marketed Outside US

First approved in 2020

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C8H15NO3
Molecular Weight	173.2096
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C[C@H](NC(C)=O)C(O)=O

InChI

InChIKey=WXNXCEHXYPACJF-ZETCQYMHSA-N

InChI=1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)/t7-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C8H15NO3
Molecular Weight	173.2096
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26607469
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/13523909 | https://www.ncbi.nlm.nih.gov/pubmed/27083881 | http://adisinsight.springer.com/drugs/800029130

L-Acetylleucine is enantiomer of Acetylleucine that used in the treatment of vertigo and cerebellar ataxia. The N-acetyl-L-leucine isomer is the active part of the racemate component since it induces a significant acceleration of the vestibular compensation process similar and even better than that observed under treatment with the racemate component only. Acetylleucine was aggressively marketed in France for vertigo. It may act as a precursor of a peptidic neuromediator responsible for activation of vestibular afferents. It may also have ‘anticalcium’ properties on neurotransmission. Pierre Fabre conducted clinical studies of L-Acetoleusine for Vertigo and Dizzinesstherapy. However, all clinical studies were discontinued

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Vertigo 17 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27083881	Primary		Approved 8429	Acétylleucine Approved Use Unknown

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

On average 3 to 4 tablets (1 tablet = 500mg DL-Acetylleucine) in two doses morning and evening.

Route of Administration: Oral

In Vitro Use Guide

Intracellular recordings were obtained from 33 neurons within the MVN with 3 M K-acetate-containing glass microelectrodes (70±120 MW), taking the border of the fourth ventricle as a landmark. The mean activity of each neuron and the effects of acetyl-DL-leucine were established by monitoring the membrane potential, the membrane resistance and the spontaneous firing rate of the cell. Since in control medium, most MVN neurons display a spontaneous, regular discharge, their `mean membrane potential' was defined as the membrane potential value measured in the middle of each interspike interval. Acetyl-DL-leucine was also applied to 30 MVN neurons recorded extracellularly, using 2 M NaCl-containing glass microelectrodes (2±8 MW). Data obtained through an Axoclamp 2A amplifier (Axon Instruments, Foster City, California, USA) were followed online on a paper chart recorder

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:23:38 GMT 2023` Edited by `admin` on `Sat Dec 16 08:23:38 GMT 2023`
Record UNII	E915HL7K2O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ACETYLLEUCINE, L-

Common Name

English

N-ACETYL LEUCINE

Common Name

English

N-ACETYL-L-(-)-LEUCINE

Systematic Name

English

ACETYL-L-LEUCINE

Systematic Name

English

ACETYLLEUCINE, (S)-

Systematic Name

English

N-ACETYLLEUCINE

Systematic Name

English

N-ACETYL-L-LEUCINE [USP-RS]

Common Name

English

LEUCINE, N-ACETYL-, L-

Systematic Name

English

NSC-206316

Code

English

N-ACETYL-L-LEUCINE

Systematic Name

English

N-Acetyl-Leucine

Common Name

English

L-LEUCINE, N-ACETYL-

Systematic Name

English

(S)-2-ACETAMIDO-4-METHYLPENTANOIC ACID

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

914022